The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a once-daily oral drug developed by Revolution Medicines for adults with metastatic pancreatic adenocarcinoma. These adults must have received at least one prior systemic therapy or are not candidates for multiagent chemotherapy.

The August 26 approval gives patients with advanced pancreatic cancer a new targeted treatment option. This follows results from a Phase 3 trial that showed a substantial survival benefit compared with standard chemotherapy. The FDA said median overall survival reached 13.2 months with Rasonque, compared with 6.7 months with chemotherapy.

The results make Rasonque one of the most significant recent developments in the treatment of metastatic pancreatic cancer. This disease has historically been difficult to treat and is often diagnosed after it has already spread.

Rasonque targets RAS, a major driver of pancreatic cancer

Rasonque is designed to inhibit the RAS family of proteins, which play a central role in signaling pathways that can drive cancer growth. In fact, research from the National Cancer Institute shows that more than 90% of pancreatic cancers have mutations in the KRAS gene. Therefore, RAS signaling has become a major focus of current drug development.

Unlike conventional chemotherapy, which broadly attacks rapidly dividing cells, Rasonque is a targeted therapy. It is designed to interfere directly with cancer-driving RAS activity.

The FDA approved the drug for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment or who cannot receive combination systemic therapy. Importantly, the approval does not require patients to have a specific identified RAS mutation.

That distinction could expand the number of patients who may be considered for the treatment.

Phase 3 trial showed a major survival advantage

The FDA based its decision on the RASolute 302 trial, a randomized Phase 3 study involving 500 patients with metastatic pancreatic adenocarcinoma. All these patients had disease that had progressed after previous treatment.

Patients received either once-daily Rasonque or one of several standard chemotherapy regimens.

The results were striking. Median overall survival was 13.2 months for patients receiving Rasonque, compared with 6.7 months for those receiving chemotherapy. The treatment also reduced the risk of death by 60%, according to the FDA and Revolution Medicines.

Rasonque also improved progression-free survival. Patients receiving the drug had a median progression-free survival of 7.2 months, compared with 3.6 months for chemotherapy.

The trial also reported improvements in patient-reported quality of life. The time before deterioration in overall health status was 5.7 months with Rasonque versus 2.6 months with chemotherapy.

Those results help explain why the treatment attracted significant attention before receiving full FDA approval.

FDA accelerated the review

Rasonque also benefited from an expedited FDA review pathway intended to accelerate access to therapies addressing major health priorities and substantial unmet medical needs.

The FDA said the drug received approval 6.5 months before the user fee deadline. It had previously received Breakthrough Therapy and Orphan Drug designations, as well as Priority Review.

The agency also permitted expanded access in May, allowing eligible patients with previously treated metastatic pancreatic cancer to receive the investigational treatment before its formal approval.

That program helped create early access for patients while the regulatory review was still underway.

Rasonque is now available in the U.S.

Revolution Medicines said Rasonque is now available by prescription in the United States as a 300 mg once-daily oral tablet.

The company’s reported wholesale acquisition cost is $39,800 for a 30-day supply. Revolution also launched a patient-support program called (ON)Path, which is designed to help patients navigate insurance coverage, financial assistance and treatment education.

The price places Rasonque firmly in the high-cost specialty-drug market. As a result, insurance coverage and financial assistance are important factors in determining how broadly patients can access the treatment.

The drug also comes with risks

The approval does not mean Rasonque is free of significant side effects.

According to the FDA, common adverse reactions include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage. The agency also lists warnings involving dermatologic toxicity, oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.

In the clinical trial, serious adverse reactions occurred in 30% of patients treated with Rasonque, according to the company’s prescribing information. Permanent treatment discontinuation because of adverse reactions occurred in 2.9% of patients.

For patients and physicians, the potential benefit therefore needs to be weighed against the drug’s safety profile and the individual’s medical circumstances.

Why the approval matters for pancreatic cancer

Pancreatic adenocarcinoma remains one of the most challenging cancers to treat. The National Cancer Institute has noted that more than 90% of pancreatic cancers are driven by alterations in RAS genes. However, developing medicines capable of effectively targeting those proteins has been a longstanding challenge.

Rasonque represents a different approach because it directly targets active RAS signaling across a broad range of RAS variants.

The FDA described it as the first targeted therapy of its class approved for metastatic pancreatic cancer.

The significance extends beyond a single drug. Researchers have spent decades trying to turn knowledge of RAS biology into effective treatments. The approval of Rasonque provides clinical evidence that directly targeting this pathway can produce meaningful benefits for patients with advanced disease.

What comes next for Rasonque

Revolution Medicines is continuing to study daraxonrasib in other cancers and earlier stages of pancreatic cancer. The National Cancer Institute’s clinical-trial database lists an ongoing Phase 3 study. This study is evaluating daraxonrasib alone or in combination with chemotherapy as a first-line treatment for metastatic pancreatic adenocarcinoma.

The company is also developing the drug in other RAS-driven cancers.

For now, the FDA approval is limited to the specified population of adults with metastatic pancreatic adenocarcinoma. These adults must have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

The immediate impact is clear: patients with previously treated metastatic pancreatic cancer now have an FDA-approved oral targeted therapy. In a randomized Phase 3 trial, this therapy more than doubled median overall survival compared with chemotherapy.

That does not make Rasonque a cure. But for a cancer where treatment advances have historically been difficult to achieve, the approval represents a major change in the therapeutic landscape.